Bio­gen names de­vel­op­ment chief as it braces for lecanemab de­ci­sion; Zymeworks CMO is shown the door

→ While an FDA rul­ing on Ei­sai and Bio­gen’s Alzheimer’s drug lecanemab is im­mi­nent, new Bio­gen CEO Chris Viehbach­er is split­ting the role of R&D chief in­to two jobs. The hunt is on for a head of re­search, but Priya Sing­hal will lead de­vel­op­ment af­ter step­ping in as in­ter­im head of R&D for Al San­drock in No­vem­ber 2021. San­drock, mean­while, has since tak­en on a recla­ma­tion project as CEO of Voy­ager Ther­a­peu­tics. Af­ter four years at Ver­tex, Sing­hal joined Bio­gen in 2012, then left to be­come Zaf­gen’s head of R&D in 2019. She re­turned to Bio­gen less than a year lat­er as SVP, head of glob­al safe­ty and reg­u­la­to­ry sci­ences. John Car­roll lends some analy­sis about Viehbach­er’s move.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN